DASATINIB MYLAN 70 MG TBL FLM 60

What is the maximum co-payment for DASATINIB MYLAN?

If the insurance company contributes, the maximum co-payment is 21 275,72 Kč. The maximum pharmacy price is 51 159,38 Kč. A pharmacy may provide the medicine for a lower price, but not for a higher price.

Does the medicine have reimbursement from public health insurance?

A medicine whose use is, in the public interest, appropriate to concentrate in specialized facilities pursuant to Section 15(10) of the Public Health Insurance Act. The medicine is reimbursed as ZÚLP and only from a facility that has a contract with the health insurer.

Does DASATINIB MYLAN have a counted co-payment set?

No, this medicine has no counted co-payment.

How much does the insurance company pay for one dispensed reimbursed pack?

29 883,66 Kč.

Does the insurance company pay a higher amount in some cases?

No, the medicine has no increased reimbursement.

Does the medicine have an indication restriction?

Dasatinib je hrazen
1) v léčbě pacientů s nově diagnostikovanou bcr-abl pozitivní (Ph+) chronickou myeloidní leukémií (CML), u nichž na základě anamnézy, cíle léčby a aktuálního zdravotního stavu popsaných v klinické dokumentaci není ošetřujícím lékařem indikováno použití imatinibu.
2) jako léčba 2. linie po selhání či intoleranci léčby imatinibem nebo nilotinibem při CML:
a) v chronické fázi,
b) v akcelerované fázi,
c) v myeloblastickém nebo lymfoblastickém zvratu.
V obou uvedených indikacích je léčba hrazena do progrese onemocnění nebo selhání léčby.

Is it available without a medical prescription?

No, the medicine cannot be obtained without a prescription.

Which medical specialist may prescribe DASATINIB MYLAN?

Prescription is not conditional on a medical specialization.

What is the composition of DASATINIB MYLAN?

Dasatinib (70 mg), monohydrát laktosy, neznámá látka s kódem 3755, neznámá látka s kódem 4336, sodná sůl kroskarmelosy, magnesium-stearát, hypromelosa, oxid titaničitý, neznámá látka s kódem 4105. More information about the composition can be found in the SPC, section 6.1.

Where can I find information about correct use of the medicine?

Documents could not be found

Which medicines are similar to DASATINIB MYLAN?

The medicine belongs to ATC group L01EA02 – DASATINIB. Medicines with the same active substance can be found here.

Who manufactures DASATINIB MYLAN?

VIATRIS LIMITED, Dublin (IRL)

Is the medicine in shortage?

The latest report from the manufacturer is from 23. 12. 2024. Production was terminated with effect from 10. 1. 2025. The manufacturer lists medicines with the following code as a potential substitute: